A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
NCT ID: NCT00760578
Last Updated: 2013-05-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
86 participants
INTERVENTIONAL
2008-09-30
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
NCT01103414
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
NCT01280695
Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes
NCT00772174
Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes
NCT01576328
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.
NCT00727857
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Microcrystaline cellulose once daily
Placebo
Once daily, oral
Pioglitazone
Pioglitazone 45 mg once daily
Pioglitazone
Once daily, oral
MSDC-0160 90 mg
MSDC-0160 90 mg once daily
MSDC-0160 90 mg
Once daily, oral
MSDC-0160 220 mg
MSDC-0160 220 mg once daily
MSDC-0160 220 mg
Once daily, oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Once daily, oral
Pioglitazone
Once daily, oral
MSDC-0160 90 mg
Once daily, oral
MSDC-0160 220 mg
Once daily, oral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female (postmenopausal or surgically sterilized), 18 to 70 years of age.
Exclusion Criteria
* History of heart failure or previous myocardial infarction.
* Blood pressure great than 160/100 mmHg.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Metabolic Solutions Development Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerry R Colca, PhD
Role: STUDY_DIRECTOR
Metabolic Solutions Development Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Los Angeles, California, United States
Miami Gardens, Florida, United States
West Palm Beach, Florida, United States
Kalamazoo, Michigan, United States
Greenville, South Carolina, United States
Dallas, Texas, United States
San Antonio, Texas, United States
Renton, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MSDC-C003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.